Sex: U
Vaccine: FLU4, FLU4
Symptoms: No adverse event, Product storage error
Clinical narrative: occurred for 35 hours. The temperature range was from 47.0F to 50.0F with no adverse event; Initial information received on 23-Feb-2022 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves an unknown age and unknown gender patient who experienced occurred for 35 hours. the temperature range was from 47.0f to 50.0f with no adverse event while receiving vaccines INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QIV] and INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT], while treated with INSULIN GLARGINE [TOUJEO], INSULIN LISPRO [ADMELOG], INSULIN GLARGINE, LIXISENATIDE [SOLIQUA] and INSULIN GLARGINE [LANTUS VIAL] and with the use of medical device FLUBLOK QUADRIVALENT PRE-FILLED SYRINGE.     The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient started taking TOUJEO (INSULIN GLARGINE) solostar (lot - 1F133a; expiry date, route, frequency, dose, form  and indication: unknown), ADMELOG (INSULIN LISPRO) (with an unknown batch number, route, frequency, dose, strength, form  and indication: unknown), SOLIQUA (INSULIN GLARGINE, LIXISENATIDE) (with an unknown batch number, route, frequency, dose, strength, form  and indication: unknown), LANTUS VIAL (INSULIN GLARGINE) (with an unknown batch number, route, frequency, dose, strength, form  and indication: unknown) and FLUBLOK QUADRIVALENT PRE-FILLED SYRINGE (with an unknown batch number, route, frequency, dose, strength, form  and indication: unknown). On an unknown date, the patient received a dose (route, frequency, dose, strength, form and indication: unknown) of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE lot number not reported. On an unknown date, the patient received a dose (route, frequency, dose, strength, form and indication: unknown) of suspect INFLUENZA QUADRIVAL A-B VACCINE lot number not reported.  On an unknown date the patient developed a non-serious event "occurred for 35 hours. the temperature range was from 47.0f to 50.0f with no adverse event" (product temperature excursion issue) (unknown latency) following the first dose intake and (unknown latency). It was reported "Pharmacist states that a temperature excursion of unknown origin occurred for 35 hours. The temperature range was from 47.0F to 50.0F. The products involved were unopened: FLUZONE QIV NP pre-filled syringes, FLUZONE HIGH-DOSE QUADRIVALENT, and FLUBLOK QUADRIVALENT. Caller states that TOUJEO MAX, ADMELOG, SOLIQUA, LANTUS, and ADMELOG were also involved in the excursion."  Action taken with INSULIN GLARGINE (TOUJEO), INSULIN LISPRO (ADMELOG), INSULIN GLARGINE, LIXISENATIDE (SOLIQUA), INSULIN GLARGINE (LANTUS VIAL), QUADRIVALENT INFLUENZA VACCINE (FLUZONE HIGH-DOSE QUADRIVALENT) and QUADRIVALENT INFLUENZA VACCINE (FLUZONE QIV) was not applicable.  It was not reported if the patient received a corrective treatment for the event (occurred for 35 hours. The temperature range was from 47.0F to 50.0F with no adverse event).  At time of reporting, the outcome was Unknown for the event occurred for 35 hours. the temperature range was from 47.0f to 50.0f with no adverse event.